@article{35d5dab9300148e6823a85265ed0b0f1,
title = "Treatment Approaches for Actinic Keratosis",
author = "Jansen, {Maud H. E.} and Kelleners-Smeets, {Nicole W. J.} and Klara Mosterd",
note = "Funding Information: Dr. van Vollenhoven reports receiving consulting fees from AbbVie, AstraZeneca, Biogen, Biotest (Germany), Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead Sciences, Janssen, Novartis, Pfizer, Servier, and UCB, speaker{\textquoteright}s fees from AbbVie, AstraZeneca, Eli Lilly, Janssen, Pfizer, and UCB, and research funding from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and UCB; and Dr. Nurmohamed, receiving consulting fees from AbbVie, Cel-gene, Celltrion, Eli Lilly, Janssen, and Sanofi, speaker{\textquoteright}s fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche, and Sanofi, and research funding from AbbVie, Bristol-Myers Squibb, Cel-gene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, and Sanofi. No other potential conflict of interest relevant to this letter was reported.",
year = "2019",
month = jun,
day = "6",
doi = "10.1056/NEJMc1904535",
language = "English",
volume = "380",
pages = "2275--2276",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "MASSACHUSETTS MEDICAL SOCIETY",
number = "23",
}